This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kastrati, A. Articles by Schömig, A. Search for Related Content PubMed PubMed Citation Articles by Kastrati, A. Articles by Schömig, A.

Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting

Adnan Kastrati, MD^*, Werner Koch, PhD^*, Peter B. Berger, MD, Julinda Mehilli, MD^*, Katherine Stephenson, PhD, Franz-Josef Neumann, MD^*, Nicolas von Beckerath, MD^*, Corinna Böttiger, MD^*, Gordon W. Duff, MD, PhD and Albert Schömig, MD^*

^* Deutsches Herzzentrum München and 1. Medizinische Klinik rechts der Isar, Technische Universität Müchen, Munich, Germany
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
Interleukin Genetics, Inc., San Antonio, Texas, USA
Division of Molecular and Genetic Medicine, University of Sheffield, Sheffield, United Kingdom

View larger version (9K): [in a new window]   Figure 1 Graph showing on a logarithmic scale the odds ratios for clinical events and angiographic restenosis associated with the presence of the IL-1RN*2 allele for the entire population (left panel) and patients <60 years (right panel). ILRN = interleukin-1 receptor antagonist gene; MI = myocardial infarction; TVR = target vessel revascularization.

View larger version (24K): [in a new window]   Figure 2 Bar graph showing the decrease in the incidence of restenosis and TVR in patients <60 years with the increase in the number of IL-1RN*2 alleles. ILRN = interleukin-1 receptor antagonist gene; TVR = target vessel revascularization.